Skip to main content
Erschienen in: Annals of Surgical Oncology 4/2014

01.04.2014 | Breast Oncology

Sentinel Node Biopsy Using a Magnetic Tracer Versus Standard Technique: The SentiMAG Multicentre Trial

verfasst von: Michael Douek, MD, Joost Klaase, MD, Ian Monypenny, MD, Ashutosh Kothari, MS, Katalin Zechmeister, MD, Douglas Brown, MD, Lynda Wyld, PhD, Philip Drew, MD, Hans Garmo, PhD, Olorunsola Agbaje, PhD, Quentin Pankhurst, PhD, Bauke Anninga, MSc, Maarten Grootendorst, MSc, Bennie ten Haken, PhD, Margaret A. Hall-Craggs, MD, Arnie Purushotham, MD, Sarah Pinder, MD, On behalf of the SentiMAG Trialists Group

Erschienen in: Annals of Surgical Oncology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

The SentiMAG Multicentre Trial evaluated a new magnetic technique for sentinel lymph node biopsy (SLNB) against the standard (radioisotope and blue dye or radioisotope alone). The magnetic technique does not use radiation and provides both a color change (brown dye) and a handheld probe for node localization. The primary end point of this trial was defined as the proportion of sentinel nodes detected with each technique (identification rate).

Methods

A total of 160 women with breast cancer scheduled for SLNB, who were clinically and radiologically node negative, were recruited from seven centers in the United Kingdom and The Netherlands. SLNB was undertaken after administration of both the magnetic and standard tracers (radioisotope with or without blue dye).

Results

A total of 170 SLNB procedures were undertaken on 161 patients, and 1 patient was excluded, leaving 160 patients for further analysis. The identification rate was 95.0 % (152 of 160) with the standard technique and 94.4 % (151 of 160) with the magnetic technique (0.6 % difference; 95 % upper confidence limit 4.4 %; 6.9 % discordance). Of the 22 % (35 of 160) of patients with lymph node involvement, 16 % (25 of 160) had at least 1 macrometastasis, and 6 % (10 of 160) had at least a micrometastasis. Another 2.5 % (4 of 160) had isolated tumor cells. Of 404 lymph nodes removed, 297 (74 %) were true sentinel nodes. The lymph node retrieval rate was 2.5 nodes per patient overall, 1.9 nodes per patient with the standard technique, and 2.0 nodes per patient with the magnetic technique.

Conclusions

The magnetic technique is a feasible technique for SLNB, with an identification rate that is not inferior to the standard technique.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Zurück zum Zitat Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98:599–609.PubMedCrossRef Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98:599–609.PubMedCrossRef
3.
Zurück zum Zitat Cody HS III, Fey J, Akhurst T, et al. Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol. 2001;8:13–9.PubMedCrossRef Cody HS III, Fey J, Akhurst T, et al. Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol. 2001;8:13–9.PubMedCrossRef
4.
Zurück zum Zitat Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703–20.PubMedCrossRef Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703–20.PubMedCrossRef
5.
Zurück zum Zitat Straver ME, Meijnen P, van Tienhoven G, et al. Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol. 2010;17:1854–61.PubMedCentralPubMedCrossRef Straver ME, Meijnen P, van Tienhoven G, et al. Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol. 2010;17:1854–61.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Goyal A, Newcombe RG, Chhabra A, Mansel RE. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer: results of the ALMANAC validation phase. Breast Cancer Res Treat. 2006;99:203–8.PubMedCrossRef Goyal A, Newcombe RG, Chhabra A, Mansel RE. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer: results of the ALMANAC validation phase. Breast Cancer Res Treat. 2006;99:203–8.PubMedCrossRef
7.
Zurück zum Zitat White V, Harvey JR, Griffith CD, Youssef M, Carr M. Sentinel lymph node biopsy in early breast cancer surgery: working with the risks of vital blue dye to reap the benefits. Eur J Surg Oncol. 2011;37:101–8.PubMedCrossRef White V, Harvey JR, Griffith CD, Youssef M, Carr M. Sentinel lymph node biopsy in early breast cancer surgery: working with the risks of vital blue dye to reap the benefits. Eur J Surg Oncol. 2011;37:101–8.PubMedCrossRef
8.
Zurück zum Zitat Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391–8; discussion 398–401.PubMedCentralPubMedCrossRef Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391–8; discussion 398–401.PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Joshi T, Pankhurst QA, Hattersley S, et al. Magnetic nanoparticles for detecting cancer spread. Breast Cancer Res Treat. 2007;1006(Suppl. 1):S129. Joshi T, Pankhurst QA, Hattersley S, et al. Magnetic nanoparticles for detecting cancer spread. Breast Cancer Res Treat. 2007;1006(Suppl. 1):S129.
10.
Zurück zum Zitat Johnson L, Douek M. Magnetic sentinel lymph node detection for breast cancer. Cancer Res. 2010;70:140s.CrossRef Johnson L, Douek M. Magnetic sentinel lymph node detection for breast cancer. Cancer Res. 2010;70:140s.CrossRef
11.
Zurück zum Zitat Gunasekera UA, Pankhurst QA, Douek M. Imaging applications of nanotechnology in cancer. Target Oncol. 2009;4:169–81.PubMedCrossRef Gunasekera UA, Pankhurst QA, Douek M. Imaging applications of nanotechnology in cancer. Target Oncol. 2009;4:169–81.PubMedCrossRef
12.
Zurück zum Zitat Johnson L, Gunasekera A, Douek M. Applications of nanotechnology in cancer. Discov Med. 2010;9:374–9.PubMed Johnson L, Gunasekera A, Douek M. Applications of nanotechnology in cancer. Discov Med. 2010;9:374–9.PubMed
13.
Zurück zum Zitat Johnson L, Pinder SE, Douek M. Deposition of superparamagnetic iron-oxide nanoparticles in axillary sentinel lymph nodes following subcutaneous injection. Histopathology. 2013;62:481–6.PubMedCrossRef Johnson L, Pinder SE, Douek M. Deposition of superparamagnetic iron-oxide nanoparticles in axillary sentinel lymph nodes following subcutaneous injection. Histopathology. 2013;62:481–6.PubMedCrossRef
14.
Zurück zum Zitat Motomura K, Ishitobi M, Komoike Y, et al. SPIO-enhanced magnetic resonance imaging for the detection of metastases in sentinel nodes localized by computed tomography lymphography in patients with breast cancer. Ann Surg Oncol. 2011;18:3422–9.PubMedCrossRef Motomura K, Ishitobi M, Komoike Y, et al. SPIO-enhanced magnetic resonance imaging for the detection of metastases in sentinel nodes localized by computed tomography lymphography in patients with breast cancer. Ann Surg Oncol. 2011;18:3422–9.PubMedCrossRef
15.
Zurück zum Zitat Cserni G, Bianchi S, Boecker W, et al. Improving the reproducibility of diagnosing micrometastases and isolated tumor cells. Cancer. 2005;103:358–67.PubMedCrossRef Cserni G, Bianchi S, Boecker W, et al. Improving the reproducibility of diagnosing micrometastases and isolated tumor cells. Cancer. 2005;103:358–67.PubMedCrossRef
16.
Zurück zum Zitat Newcombe RG. Improved confidence intervals for the difference between binomial proportions based on paired data. Stat Med. 1998;17:2635–50.PubMedCrossRef Newcombe RG. Improved confidence intervals for the difference between binomial proportions based on paired data. Stat Med. 1998;17:2635–50.PubMedCrossRef
17.
Zurück zum Zitat Wishart GC, Loh SW, Jones L, Benson JR. A feasibility study (ICG-10) of indocyanine green (ICG) fluorescence mapping for sentinel lymph node detection in early breast cancer. Eur J Surg Oncol. 2012;38:651–6.PubMedCrossRef Wishart GC, Loh SW, Jones L, Benson JR. A feasibility study (ICG-10) of indocyanine green (ICG) fluorescence mapping for sentinel lymph node detection in early breast cancer. Eur J Surg Oncol. 2012;38:651–6.PubMedCrossRef
18.
Zurück zum Zitat Motomura K, Inaji H, Komoike Y, Kasugai T, Noguchi S, Koyama H. Sentinel node biopsy guided by indocyanine green dye in breast cancer patients. Jpn J Clin Oncol. 1999;29:604–7.PubMedCrossRef Motomura K, Inaji H, Komoike Y, Kasugai T, Noguchi S, Koyama H. Sentinel node biopsy guided by indocyanine green dye in breast cancer patients. Jpn J Clin Oncol. 1999;29:604–7.PubMedCrossRef
19.
Zurück zum Zitat Takeuchi M, Sugie T, Abdelazeem K, et al. Lymphatic mapping with fluorescence navigation using indocyanine green and axillary surgery in patients with primary breast cancer. Breast J. 2012;18:535–41.PubMedCrossRef Takeuchi M, Sugie T, Abdelazeem K, et al. Lymphatic mapping with fluorescence navigation using indocyanine green and axillary surgery in patients with primary breast cancer. Breast J. 2012;18:535–41.PubMedCrossRef
20.
Zurück zum Zitat Sugie T, Sawada T, Tagaya N, et al. Comparison of the indocyanine green fluorescence and blue dye methods in detection of sentinel lymph nodes in early-stage breast cancer. Ann Surg Oncol. 2013;20:2213–8.PubMedCrossRef Sugie T, Sawada T, Tagaya N, et al. Comparison of the indocyanine green fluorescence and blue dye methods in detection of sentinel lymph nodes in early-stage breast cancer. Ann Surg Oncol. 2013;20:2213–8.PubMedCrossRef
21.
Zurück zum Zitat Abe H, Mori T, Umeda T, et al. Indocyanine green fluorescence imaging system for sentinel lymph node biopsies in early breast cancer patients. Surg Today. 2011;41:197–202.PubMedCrossRef Abe H, Mori T, Umeda T, et al. Indocyanine green fluorescence imaging system for sentinel lymph node biopsies in early breast cancer patients. Surg Today. 2011;41:197–202.PubMedCrossRef
22.
Zurück zum Zitat Hojo T, Nagao T, Kikuyama M, Akashi S, Kinoshita T. Evaluation of sentinel node biopsy by combined fluorescent and dye method and lymph flow for breast cancer. Breast. 2010;19:210–3.PubMedCrossRef Hojo T, Nagao T, Kikuyama M, Akashi S, Kinoshita T. Evaluation of sentinel node biopsy by combined fluorescent and dye method and lymph flow for breast cancer. Breast. 2010;19:210–3.PubMedCrossRef
23.
Zurück zum Zitat Troyan SL, Kianzad V, Gibbs-Strauss SL, et al. The FLARE intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial in breast cancer sentinel lymph node mapping. Ann Surg Oncol. 2009;16:2943–52.PubMedCentralPubMedCrossRef Troyan SL, Kianzad V, Gibbs-Strauss SL, et al. The FLARE intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial in breast cancer sentinel lymph node mapping. Ann Surg Oncol. 2009;16:2943–52.PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat van der Vorst JR, Schaafsma BE, Verbeek FP, et al. Randomized comparison of near-infrared fluorescence imaging using indocyanine green and 99(m) technetium with or without patent blue for the sentinel lymph node procedure in breast cancer patients. Ann Surg Oncol. 2012;19:4104–11.PubMedCentralPubMedCrossRef van der Vorst JR, Schaafsma BE, Verbeek FP, et al. Randomized comparison of near-infrared fluorescence imaging using indocyanine green and 99(m) technetium with or without patent blue for the sentinel lymph node procedure in breast cancer patients. Ann Surg Oncol. 2012;19:4104–11.PubMedCentralPubMedCrossRef
Metadaten
Titel
Sentinel Node Biopsy Using a Magnetic Tracer Versus Standard Technique: The SentiMAG Multicentre Trial
verfasst von
Michael Douek, MD
Joost Klaase, MD
Ian Monypenny, MD
Ashutosh Kothari, MS
Katalin Zechmeister, MD
Douglas Brown, MD
Lynda Wyld, PhD
Philip Drew, MD
Hans Garmo, PhD
Olorunsola Agbaje, PhD
Quentin Pankhurst, PhD
Bauke Anninga, MSc
Maarten Grootendorst, MSc
Bennie ten Haken, PhD
Margaret A. Hall-Craggs, MD
Arnie Purushotham, MD
Sarah Pinder, MD
On behalf of the SentiMAG Trialists Group
Publikationsdatum
01.04.2014
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe 4/2014
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-3379-6

Weitere Artikel der Ausgabe 4/2014

Annals of Surgical Oncology 4/2014 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.